regorafenib

Overview

Regorafenib is an oral multi-kinase inhibitor with FDA approvals in metastatic colorectal cancer, hepatocellular carcinoma, and gastrointestinal stromal tumors. In osteosarcoma, it is listed in NCCN guidelines for relapsed/refractory disease.

Evidence in the corpus

• In the UCLA PDTO sarcoma screen, regorafenib was one of the recurrent NCCN-listed top-five regimens identified for osteosarcoma samples; it appeared alongside sorafenib, etoposide, cisplatin, doxorubicin, cabozantinib, gemcitabine, docetaxel, and everolimus as the actionable backbone for osteosarcoma in the functional precision-medicine framework. PMID:39305899
• RESORCE trial (post-sorafenib HCC): regorafenib median OS 10.6 vs 7.8 months (HR 0.63, 95% CI 0.50–0.79, P<0.0001); FDA-approved second-line for patients who tolerated and progressed on sorafenib PMID:24798001
• Nominated for Triple-WT melanoma subtype (14% of 318 TCGA cases) to target co-amplified PDGFRA/KDR at 4q12 alongside imatinib, dasatinib, sorafenib, crenolanib, and pazopanib PMID:26091043
• Multi-kinase inhibitor (PDGFRA/KDR/KIT co-amplification); used as targeted therapy in 4 recurrent/metastatic adenoid cystic carcinoma (ACYC) patients matched by MSK-IMPACT profiling in head and neck cancer basket study PMID:27442865

Resistance mechanisms

• Not reported in corpus.

Cancer types (linked)

• OS

Sources

• PMID:39305899 — Duminuco et al. 2024, UCLA PDTO sarcoma functional screen; NCCN-listed osteosarcoma activity.

This page was processed by crosslinker on 2026-05-14. - PMID:24798001

This page was processed by crosslinker on 2026-05-14. - PMID:26091043

This page was processed by crosslinker on 2026-05-14. - PMID:27442865

This page was processed by wiki-cli on 2026-05-14.